A monoclonal anti-PlGF antibody against mouse PlGF (5D11D4), developed by ThromboGenics NV (Heverlee, Belgium), was previously shown to inhibit tumour growth in different mouse tumour models 26,27. This evidence concerns the gene PGF and neoplasm.